What we do Bacil Pharma Ltd is a leading Indian pharmaceutical company engaged in manufacturing and marketing prescription drugs, branded formulations, APIs, OTC products, and intravenous infusions across India. |
Founded in 1,987 |
Market share Strong domestic presence with wide distribution and 500+ field force; emerging as a notable player in specialty and herbal medicine segments. |
Problem solved Providing accessible healthcare solutions through quality medicines in various therapeutic areas, bridging gaps in healthcare needs and medicine availability. |
Top clients or who we serve Serving hospitals, government bodies, retailers, and consumers across India via B2B and B2C channels with a focus on therapeutic specialties. |
Key management - |
Our journey and innovations Founded in 1987; transitioned from private to public in 1988; expanded manufacturing facilities and acquired existing bulk drug units to boost production capabilities. |
Where we operate Primarily operates across India with distribution in all states and districts, serving institutional and retail customers nationwide. |
Top products or what we offer Tablets, capsules, intravenous fluids, ophthalmic and liquid oral preparations, branded formulations like Aziwin, Balvibe, and Monogesic Plus Gel. |
Top brands Aziwin (key prescription brand), Ebay, Balvibe, MNF, Ocium, Monogesic Plus Gel (India's first innovative pain-relieving gel), Bal Vedics herbal products. |
Raw materials needed Active pharmaceutical ingredients (APIs), chemical compounds for formulations, herbal extracts for Ayurvedic products. |
Raw materials supplier Not specified; company owns API manufacturing producing key raw materials in-house. |
Recurring vs cyclical contribution Revenue mostly cyclical with product sales; recent years saw lower operational income with emphasis on financial management and investments. |
Our industry position Well-established in Indian pharmaceutical market with strong institutional ties and increasing portfolio diversification into specialty and herbal medicines. |
Financial highlights FY2025 Revenue from operations was nil; profit after tax improved to Rs 40.05 lakhs driven by other income; controlled expenses ensured profitability turnaround. |
Geographical revenue split Revenue primarily from domestic Indian market; no exports reported in FY2025. |
Order book - |
Whats driving growth Growth driven by expanding product portfolio, strategic investments in associate companies, and strengthening distribution and institutional partnerships. |
Our future plans Actively exploring business opportunities to generate sustainable revenue; increasing strategic investment in associate company CNX Corporation Limited. |
Our green promise Initiatives to reduce energy consumption through LED lighting and machinery maintenance; focus on energy-efficient processes. |
Our people and values Strong field force of over 500 employees nationwide; culture centered on ethics, compliance, and continuous improvement. |
Key challenges ahead Limited recent operational revenue; dependency on financial income and need to revitalize core business operations. |
Interesting facts Pioneer of India's first innovative pain-relieving gel; robust presence across multiple pharmaceutical specialties including herbal integration. |
Risks and strategy Risks include operational inactivity and market competition; strategy focuses on cost control, investments, and diversifying product offerings. |
